Prof. Christophe Le Tourneau

"WAYFIND-R is a unique public/private initiative that will help move forward precision medicine in the field of oncology. With WAYFIND-R, investigators will have the opportunity to answer scientific questions that could not be addressed without this large real-world clinico-genomic database. In addition, WAYFIND-R will likely accelerate drug approvals for small patient populations."

Prof. Christophe Le Tourneau, MD, PhD, is senior Medical Oncologist at the Institut Curie and Full Professor of Medicine at Paris-Saclay University. He is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic.

Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007. He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program.

His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology. He ran the first randomised precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advances cancer. He has published 200+ peer-reviewed papers in international journals.

LINK: https://institut-curie.org/personne/christophe-le-tourneau